Luísa Mendonca, None;
Jeffrey Heier, 4DMT, Adverum, Aerie, Aerpio, Aldeyra, Allegro, Allergan, Annexon, Apellis, Array, Asclepix, Eloxx, Galimedix, Genentech, Generation Bio, Gyroscope, Interface, iRenix, Janssen R&D, jCyte, Kala, Kanghong, Kodiak, NGM Biopharmaceuticals, Notal Vision, Novartis, Ocugenix, Ocular Therapeutix, Regeneron, Regenxbio, Retrotope, Santen, Scifluor, Shire, Stealth Biotherapeutics, Takeda, Voyant (C), Adverum, Allegro, jCyte, Ocular Therapeutix (I), Aerie, Aerpio, Apellis, Clearside, Daiichi Sankyo, Genentech/Roche, Graybug, Gyroscope, Hemera, Janssen R&D, Kalvista, Kanghong, Novartis, Ophthotech, Optos, Regeneron, Regenxbio, Stealth Biotherapeutics (S);
David Boyer, Alcon (C), Allegro (C), Allegro (I), Allergan (C), Bayer (C), Chengdu Kanghong Biotechnology (C), DigiSight (I), Ohr Pharmaceuticals, Inc, (I), Regeneron (C);
David Brown, Novartis, Regeneron, Bayer, Genentech/Roche, Adverum, Kodiak, Senju, ChengduKanghong Biotechnology, Boehringer Ingelheim, Allegro, Apellis, Geminni, Regenxbio, NEI, NGM, Ionis. Stealth, Outlook Therapeutics, Xbrane, Santen, Graybug, Heidelberg (F), Novartis, Regeneron, Bayer, Genentech/Roche, Optos, Adverum, Kodiak, Senju, ChengduKanghong Biotechnology, Boehringer Ingelheim, Allegro, Apellis, Geminni, Regenxbio, Ocular Therapeutic, Stealth, Santen, iRenix Lineage Cell, Heidelberg, Navilas (C);
Sumit Shah, Alimera Sciences, Inc, Paladin Study (F), Genentech, Inc, a Roche Group, (F), Glaxosmithkline (F), Jaeb Center for Health Research, DRCR Study (F), National Institutes of Health, SCORE 2 Study - PI (F), Ohr Pharmaceuticals, Inc, (F), Opthea, Ltd, (F), Regeneron Pharmaceuticals, Inc (F), University of Virginia (F);
A. Yasin Alibhai, None;
Namrata Saroj, Allegro (C), Allegro (I), Apellis (C), Regeneron (C);
Sabin Dang, Regeneron (C);
Nadia Waheed, Apellis (C), Apellis (S), Astellas (C), Astellas (S), Boehringer Ingelheim (C), Boehringer Ingelheim (S), Boston Image Reading Center (I), Carl Zeiss Meditec (S), Gyroscope (S), Nidek Medical Products (R), Novartis (C), Novartis (S), Ocudyne (I), Regeneron (C), Roche/Genentech (C), Roche Genentech (S), Topcon (C), Topcon (S)